Pediatric neuroenhancement: Ethical, legal, social, and neurodevelopmental implications

Neurology

Volumn 80, Issue 13, 2013, Pages 1251-1260

  Graf, William D ^a   Nagel, Saskia K ^b   Epstein, Leon G ^c   Miller, Geoffrey ^a   Nass, Ruth ^d   Larriviere, Dan ^e  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF OSNABRÜCK   (Germany)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 METHYL 2 HEXYLAMINE; 5 HYDROXYTRYPTOPHAN; AMPHETAMINE; ARMODAFINIL; ATOMOXETINE; BIFEMELANE; CAFFEINE; DEANOL; DEXAMPHETAMINE; DIHYDROERGOTOXINE MESILATE; FLUOXETINE; HUPERZINE A; HYPERICUM PERFORATUM EXTRACT; METHYLPHENIDATE; MODAFINIL; NICOTINE; PHOSPHATIDYLSERINE; PIRACETAM; RESVERATROL; RHODIOLA ROSEA EXTRACT; SEROTONIN UPTAKE INHIBITOR; TAURINE; VALERIAN; VINPOCETINE; VITAMIN B GROUP;

ATTENTION DEFICIT DISORDER; BENEFICENCE; BRAIN FUNCTION; CHILD ABUSE; CHILD CARE; CHILD DEVELOPMENT; DECISION MAKING; ETHICS; GINKGO BILOBA; HUMAN; LEGAL ASPECT; MEDICAL PRACTICE; NERVOUS SYSTEM DEVELOPMENT; PATIENT AUTONOMY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SOCIAL CARE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DECISION MAKING; DRUG PRESCRIPTIONS; ETHICS, MEDICAL; HUMANS; MORALS; PEDIATRICS;

EID: 84876258053     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318289703b     Document Type: Review

References (59)

1. Parens E. Enhancing Human Traits: Ethical and Social Implications. Washington: Georgetown University Press; 1998.
2. Farah MJ, Illes J, Cook-Deegan R, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004;5:421-425.
3. Nagel SK. Ethics and the Neurosciences: Ethical and Social Consequences of Neuroscientific Progress. Paderborn: Mentis; 2010.
4. Smith ME, Farah MJ. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 2011;137:717-741.
5. Maher B. Poll results: look who's doping. Nature 2008; 452:674-675.
6. Mayes R, Bagwell C, Erkulwater J. ADHD and the rise in stimulant use among children. Harv Rev Psychiatry 2008; 16:151-166.
7. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 2009;124:875-880.
8. Larriviere D, Williams MA, Rizzo M, Bonnie RJ; the AAN Ethic LaHC. Responding to requests from adult patients for neuroenhancements. Guidance of the Ethics, Law and Humanities Committee. Neurology 2009;73:1406-1412.
9. Kass L. Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC: The President's Council on Bioethics; 2003.
10. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev 2008;1:255-262.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
12. International Narcotics Control Board. Report of the International Narcotics Control Board for 2005 [Online]. New York: International Narcotics Control Board; 2005.
13. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 suppl):26S-49S.
14. Elliott C. Enhancement technologies and the modern self. J Med Philos 2011;36:1-11.
15. Chatterjee A. Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Camb Q Healthc Ethics 2007;16:129-137.
16. Sandel M. The Case Against Perfection. Cambridge: Harvard University Press; 2006.
17. Stirling J. American Academy of Pediatrics Committee on Child Abuse and Neglect. Beyond Münchausen syndrome by proxy: identification and treatment of child abuse in a medical setting. Pediatrics 2007;119:1026-1030.
18. Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/ hyperactivity disorder among children - United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439-1443.
19. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 2006;84:135-143.
20. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord 2007;10:335-342.
21. Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10 2008;10:1-14.
22. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1025-1030.
23. Leibson Cl, Long KH. Economic implications of attentiondeficit hyperactivity disorder for healthcare systems. Pharmacoeconomics 2003;21:1239-1262.
24. Riddle MA, Kastelic EA, Frosch E. Pediatric psychopharmacology. J Child Psychol Psychiatry 2001;42:73-90.
25. Singh I. Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD. Am J Bioethics 2005;5:34-47.
26. Elder TE. The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates. J Health Econ 2010;29:641-656.
27. Christakis DA, Zimmerman FJ, DiGiuseppe DL, McCarty CA. Early television exposure and subsequent attentional problems in children. Pediatrics 2004;113: 708-713.
28. McCabe SE, West BT, Cranford JA, et al. Medical misuse of controlled medications among adolescents. Arch Pediatr Adolesc Med 2011;165:729-735.
29. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975-2008. Volume I: Secondary School Students (NIH Publication No. 09-7402). Bethesda, MD: National Institute on Drug Abuse; 2009.
30. Bucher R Non-Medical Use of Methylphenidate: Defining the Problem, Creating Solutions. Bethesda, MD: Institute for Behavior and Health; 2004.
31. Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 6th ed. New York: Oxford University Press; 2008.
32. American Academy of Pediatrics Committee on Bioethics. Informed consent, parental permission, and assent in pediatric practice. Pediatrics 1995;95:314-317.
33. Dworkin G. The Theory and Practice of Autonomy. New York: Cambridge University Press; 1988.
34. Christman J. The Politics of Persons: Individual Autonomy and Socio-Historical Selves. Cambridge: Cambridge University Press; 2009.
35. Berlan ED, Bravendar T. Confidentiality, consent, and caring for the adolescent population. Curr Opin Pediatr 2009;21:450-456.
36. Feinberg J. A child's right to an open future. In: Aiken W, LaFollette H, eds. Whose Child? Totowa: Rowman and Littlefield; 1980.
37. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-1448.
38. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-1904.
39. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003;27:615-621.
40. Kim Y, Merilee A, Teylan MA, et al. Methylphenidateinduced dendritic spine formation and delta FosB expression in nucleus accumbens. Proc Natl Acad Sci USA 2009; 106:2915-2920.
41. O'Leary JC. An analysis of the legal issue surrounding the forced use of Ritalin: protecting a child's right to "just say no." N Engl Law Rev 1993;27:1173-1209.
42. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008;456:702-705.
43. Conrad P. The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders. Baltimore: Johns Hopkins Press; 2007.
44. Lane C. Shyness: How Normal Behavior Became a Sickness. New Haven: Yale University Press; 2007.
45. Parens E. On good and bad forms of medicalization. Bioethics 2011;25.
46. Kramer PD. Listening to Prozac. New York: Penguin Books; 1993.
47. Vannini P, Williams P, eds. Authenticity in Culture, Self, and Society. London: Ashgate Publishing; 2009.
48. Guignon C. On Being Authentic. London: Routledge; 2004.
49. Keller H. Cultures of Infancy. Mahwah: Erlbaum; 2007.
50. Singh I. Clinical implications of ethical concepts: moral self-understandings in children taking methylphenidate for ADHD. Clin Child Psychol Psychiatry 2007;12: 167-182.
51. Fraser AD. Doping control from a global and national perspective. Ther Drug Monit 2004;26:171-174.
52. McCabe SE, West BT, Teter CJ, Ross-Durow P, Young A, Boyd CJ. Characteristics associated with the diversion of controlled medications among adolescents. Drug Alcohol Depend 2011;118:452-458.
53. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002;346:498-505.
54. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med 2005;352: 325-328.
55. Friedman M, Gould J. Consumer attitudes and behaviors associated with direct-to-consumer prescription drug marketing. J Consum Market 2007;24:100-109.
56. Mintzes B, Barer ML, Kravitz RL, et al. How does directto-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003;169:405-412.
57. Kupfer DJ, First MB, Regier DA, eds. A Research Agenda for DSM-V. Washington: American Psychiatric Association; 2002.
58. Eriksen K, Kress VE. Beyond the DSM Story: Ethical Quandaries, Challenges, and Best Practices. Thousand Oaks: Sage; 2005.
59. Beutler LE, Malik ML, eds. Rethinking the DSM: A Psychological Perspective. Washington: American Psychiatric Association; 2002.